Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells NEW YORK, March 31, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National Intellectual Property Administration (CNIPA) has granted Chinese Patent, titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells." The patent, originally filed under PCT Application No.